Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Treatment of NMO relapse in the elderly: rituximab when plasma exchange fails?
A comparative study of CSF neurofilament light and heavy chain protein in MS.
The effect of gabapentin on oxidative stress in a model of toxic demyelination in rat brain.
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
Nogo-A: Multiple Roles in CNS Development, Maintenance, and Disease.
Axonal Loss in a Rat Model of Optic Neuritis Is Closely Correlated with Visual Evoked Potential Amplitudes Using Electroencephalogram-based Scaling.
Compressive syndrome of internal jugular veins in multiple sclerosis: does it matter?
Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis.
The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects.
A cluster randomised controlled trial on the efficacy of client-centred occupational therapy in multiple sclerosis: good process, poor outcome.
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis.
The relation between peptide hormones and sex hormone in patients with multiple sclerosis.
Neuroprotection in Huntington's disease: a 2-year study on minocycline.
dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis.
Central nervous system myeloid cells as drug targets: current status and translational challenges.
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
Brain imaging and bladder function.
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis.
Mesenchymal Stem Cell treatment for autoimmune diseases: a critical review.
Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function.

Pages